Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trialResearch in context

• Main Authors: María Eugenia Toledo-Romaní (Author), Mayra García-Carmenate (Author), Carmen Valenzuela-Silva (Author), Waldemar Baldoquín-Rodríguez (Author), Marisel Martínez-Pérez (Author), Meiby Rodríguez-González (Author), Beatriz Paredes-Moreno (Author), Ivis Mendoza-Hernández (Author), Raúl González-Mujica Romero (Author), Oscar Samón-Tabio (Author), Pablo Velazco-Villares (Author), Juan Pablo Bacallao-Castillo (Author), Ernesto Licea-Martín (Author), Misladys Rodríguez-Ortega (Author), Nuris Herrera-Marrero (Author), Esperanza Caballero-González (Author), Liudmila Egües-Torres (Author), Reinaldo Duartes-González (Author), Serguey García-Blanco (Author), Suzette Pérez-Cabrera (Author), Santos Huete-Ferreira (Author), Kirenia Idalmis-Cisnero (Author), Omayda Fonte-Galindo (Author), Dania Meliá-Pérez (Author), Ivonne Rojas-Remedios (Author), Delaram Doroud (Author), Mohammad Mehdi Gouya (Author), Alireza Biglari (Author), Sonsire Fernández-Castillo (Author), Yanet Climent-Ruiz (Author), Yury Valdes-Balbín (Author), Dagmar García-Rivera (Author), Patrick Van der Stuyft (Author), Vicente Verez-Bencomo (Author)
• Format: Book
• Published: Elsevier, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting neutralising IgG and specific T-cell response. A third heterologous dose of SOBERANA-Plus (RBD-dimer) further increa...